Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2024-04-12 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-04-12 English
Retirement
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding changes in the company's board of directors, specifically the retirement of four Independent Directors after completion of their second term. It also details the reconstitution of various board committees following these retirements. The document references compliance with SEBI Listing Regulations and includes an annexure with details about the director changes. There is no financial data, earnings information, or report publication mentioned. The content clearly pertains to changes in the company's board and management structure, fitting the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure about management changes.
2024-04-01 English
Credit Rating
Regulatory Filings
2024-03-20 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a detailed research update from S&P Global Ratings regarding Glenmark Pharmaceuticals' credit rating upgrade to 'BB+'. It includes extensive financial analysis, assumptions, outlook, liquidity assessment, and risk factors. The content focuses on credit rating rationale, financial metrics, and company business position rather than being a regulatory filing, earnings release, or annual/interim report. It is not a certification or a brief announcement but a comprehensive credit rating report. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides an update on the company's credit rating and financial position related to debt paydown and capital structure changes.
2024-03-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges and regulatory bodies, referencing a previous disclosure about the sale of equity shares representing a significant portion of the company's stake in Glenmark Life Sciences Limited. It details the completion of the transfer of remaining shares under a share purchase agreement. The document is short (2220 characters), primarily serves as an announcement of a transaction completion, and is regulatory in nature. It does not contain financial statements, detailed financial analysis, or management discussion. It is not a full report but a regulatory disclosure pursuant to SEBI Listing Obligations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about a share sale transaction.
2024-03-12 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the sale of a significant portion of equity shares of a subsidiary company, Glenmark Life Sciences Limited, to another company, Nirma Limited. It references a share purchase agreement and provides an update on the transfer of shares. The content is an announcement of a capital transaction involving share transfer and ownership change. The document length is short (2050 characters) and it is not a full financial report or detailed analysis. It is not an earnings release, annual report, or management discussion. It is not a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to a significant financing/capital transaction update involving share transfer and ownership change.
2024-03-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.